Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

284
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
284

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Light-Activated Metal-Dependent Protein Degradation: A Heterobifunctional Ruthenium(II) Photosensitizer Targeting New Delhi Metallo-β-lactamase 1.

Journal of the American Chemical Society·2025
Same author

Solid-state NMR of membrane peptides and proteins in the lipid cubic phase.

Biophysical journal·2025
Same author

Computational Design of Cyclic Peptide Inhibitors of a Bacterial Membrane Lipoprotein Peptidase.

ACS chemical biology·2024
Same author

Dive Hazards: Barotrauma, Flora, Fauna, Equipment, and Free Diving.

Current sports medicine reports·2024
Same author

Epidemiology of Craniomaxillofacial Fractures Over a 5-year Period at a Midwestern Level 1 Trauma Center Serving a Large Rural Population.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons·2024
Same author

Association between anesthesia technique and death after hip fracture repair for patients with COVID-19.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2023

Related Experiment Video

Updated: Oct 6, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.4K

Cluster Headache: Rapid Evidence Review.

Omojo Odihi Malu1, Jonathan Bailey1, Matthew Kendall Hawks2

  • 1DiLorenzo TRICARE Health Clinic, Pentagon, Washington, DC, USA.

American Family Physician
|January 14, 2022
PubMed
Summary
This summary is machine-generated.

Cluster headache, a severe primary headache disorder, causes intense unilateral pain and autonomic symptoms. Treatments range from abortive therapies like oxygen to prophylactic options such as verapamil and newer agents like galcanezumab.

More Related Videos

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.0K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

8.6K

Related Experiment Videos

Last Updated: Oct 6, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.4K
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.0K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

8.6K

Area of Science:

  • Neurology
  • Headache Medicine

Background:

  • Cluster headache is the most common trigeminal autonomic cephalgia, affecting less than 1% of the population.
  • It typically begins around age 30 and is more prevalent in males.
  • Characterized by severe unilateral orbital, supraorbital, or temporal pain attacks.

Purpose of the Study:

  • To provide a comprehensive overview of cluster headache.
  • To detail its clinical presentation, triggers, and management strategies.

Main Methods:

  • Review of existing literature on cluster headache.
  • Classification of treatments into abortive, transitional, and prophylactic categories.

Main Results:

  • Attacks occur 1-8 times daily, lasting 15-180 minutes, with associated autonomic symptoms (e.g., lacrimation, rhinorrhea, ptosis).
  • Common triggers include alcohol, nitrates, and strong odors.
  • Established treatments include triptans, oxygen, steroids, verapamil, lithium, melatonin, and topiramate.

Conclusions:

  • Cluster headache management involves a multi-faceted approach.
  • Emerging treatments like galcanezumab and neurostimulation offer new therapeutic avenues.